Asymptomatic Carotid Stenosis: When to Treat vs Watch
Bikash Roy
Online Research Specialist · SEO Strategist · Web Developer
Bikash personally verifies every calculator against official standards (WHO, NIH, government data). Online research specialist, SEO strategist, and web developer with 10+ years building accurate digital tools.
Full bio →What Is Asymptomatic Carotid Stenosis?
A patient has asymptomatic carotid stenosis if imaging identifies significant ICA narrowing but the patient has had no TIA, stroke, or amaurosis fugax attributable to that artery within the past 6 months. Asymptomatic stenosis is frequently detected incidentally on ultrasound performed for other reasons, or during cardiovascular risk screening.
Use the NASCET Calculator to quantify the stenosis degree. This article addresses the management decision once the degree is known.
The key clinical question: does CEA (or CAS) benefit this patient, or is optimized medical therapy alone sufficient?
The Original Evidence: ACAS Trial (1995)
The Asymptomatic Carotid Atherosclerosis Study (ACAS, 1995) compared CEA + aspirin vs aspirin alone in patients with asymptomatic ≥60% carotid stenosis (NASCET method).
Key findings:
- 5-year ipsilateral stroke risk: 5.1% (CEA) vs 11.0% (medical alone)
- Absolute risk reduction: 5.9% over 5 years (1.2% per year)
- Relative risk reduction: 53%
- NNT: ~17 over 5 years (much less compelling than the NNT ≈ 6 for symptomatic ≥70%)
Important caveats from ACAS:
- Perioperative stroke/death rate was only 1.5% — far below what many real-world centers achieve
- The 11% 5-year stroke risk was the baseline in 1995 — before high-intensity statins and modern dual antiplatelet therapy existed
- Women showed no significant benefit (CEA benefit was confined to men in ACAS)
Why the ACAS Evidence Is Now Questioned
The medical therapy available in 1995 (when ACAS enrolled patients) was substantially weaker than current best medical therapy:
| Treatment era | Annual stroke risk in medically managed asymptomatic patients |
|---|---|
| 1990s (ACAS era) | ~2.2% per year |
| 2000s (moderate statin era) | ~1.5–2.0% per year |
| 2010s–2020s (high-intensity statin + dual antiplatelet) | ~0.5–1.5% per year |
Contemporary data suggest the annual stroke risk from asymptomatic carotid stenosis managed with optimal medical therapy has fallen to approximately 1% per year — meaning the absolute benefit of surgical intervention is smaller than ACAS measured.
If the annual stroke risk on best medical therapy is 1%, and CEA has a perioperative stroke risk of ~1.5–3%, the procedure may not provide net benefit for many asymptomatic patients, especially for shorter remaining life expectancy.
CREST-2: The Active Ongoing Trial
CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) was designed to directly address whether CEA + intensive medical therapy is superior to intensive medical therapy alone in asymptomatic ≥70% stenosis.
CREST-2 enrolled two parallel trials: CEA vs medical management, and CAS vs medical management.
Status as of 2025–2026: CREST-2 results are expected but not yet fully published. The intensive medical therapy arm has shown lower-than-expected event rates, reinforcing the concern that surgical intervention thresholds based on ACAS data may need revision.
This trial represents the current knowledge gap — the field is awaiting definitive data on whether surgery adds benefit over contemporary best medical therapy for asymptomatic disease.
Current Guideline Recommendations
Despite uncertainty, guidelines continue to support selective intervention for asymptomatic stenosis:
| Stenosis degree | Symptomatic status | Guideline recommendation |
|---|---|---|
| < 60% | Asymptomatic | Medical management only |
| 60–79% | Asymptomatic | Medical management; CEA may be considered in low surgical risk patients at centers with < 3% perioperative risk |
| ≥ 80% | Asymptomatic | CEA reasonable if life expectancy > 5 years and perioperative risk < 3% |
Key AHA/ASA statement: CEA is only recommended for asymptomatic patients when the surgeon’s documented perioperative stroke/death rate is < 3%. At centers with higher procedural risk, medical management is preferred.
Who Benefits From CEA for Asymptomatic Disease?
Subgroups of asymptomatic patients who may derive more benefit from CEA:
Higher annual stroke risk on medical therapy (favors surgery):
- Contralateral carotid symptoms or occlusion
- Rapid progression of stenosis (≥20% increase in diameter stenosis over 6–12 months)
- Silent cerebral infarcts on MRI ipsilateral to stenosis (suggesting active embolism despite being “asymptomatic”)
- Spontaneous microemboli detected on transcranial Doppler (TCD) — indicates active embolism from plaque
- Severe (≥80%) stenosis in men under 75 with low surgical risk
Lower annual stroke risk on medical therapy (favors medical management):
- Women (ACAS showed no clear benefit in women)
- Age ≥ 80 (shorter life expectancy means less cumulative benefit from CEA, given perioperative risk)
- Multiple comorbidities increasing surgical risk
- Well-controlled risk factors with LDL < 70 mg/dL, BP controlled, non-smoker
- Stable plaque on serial imaging over 2+ years
The Watchful Waiting Approach
For asymptomatic patients managed non-operatively:
Surveillance imaging: Duplex ultrasound every 6 months for moderate stenosis (50–79%); every 3–6 months for severe stenosis (≥80%). The goal is to detect rapid progression or the onset of new symptoms that would convert the patient to a symptomatic indication.
Medical optimization: Begin high-intensity statin, antiplatelet, blood pressure control, and lifestyle modification immediately. See Carotid Stenosis Medical Management for full protocol.
Convert to symptomatic pathway if: The patient develops any ipsilateral TIA, stroke, or amaurosis fugax during watchful waiting — at that point, the evidence for urgent CEA within 2 weeks applies (see Symptomatic Carotid Stenosis Management).
The evolving standard: The field is moving toward more individualized risk assessment using TCD microemboli, plaque characteristics (ulceration, plaque echolucency indicating lipid-rich/hemorrhagic content), and perfusion imaging — rather than degree of stenosis alone — to select patients most likely to benefit from intervention.
Clinical note: Asymptomatic carotid stenosis management is an area of active research and evolving evidence. Decisions should be made with a multidisciplinary neurovascular team and in full discussion with the patient, incorporating current institutional outcomes data and patient preferences.